Data presented SITC (Society for Immunotherapy of Cancer) not only further supports eilagimod alpha ("ei") efficacy in metastac breast ("mBC") and head and neck ("HNSCC") cancers, but also highlights a potenal central role for ei across cancer therapy. Interim overall survival (“OS”) from the AIPAC was already posive, this final data is slightly improved with a clear 2.9 month increase in OS with ei+ paclitaxel. While this was not stascally significant, there was a significant increase in quality of life ("QoL") across the populaon and in OS in large paent subgroups amounng to 60% of the populaon. This included paents <65 years, those pre-treated with CDK 46 treatment, with luminal B or parcularly with a low starng monocyte count where there was an impressive 19.6-month OS increase. Further data from Phase IIa TACTI-002 supported the efficacy of ei-pembrolizumab ("ei-pembro") combinaon in HNSCC. These data not only supportthe connued development of ei in mBC in the AIPAC-03 Phase III andHNSCC in TACTI-003 Phase 2b, but also the broad potenal of ei combinaonsin cancertherapy. Safe and well tolerated ei is already showing synergy with an-PD-L1 and chemo, we believe analysis of the mBC subgroups could lead to addional combinaons; parcularly with agents that impact monocyte acvity. We reiterate and maintain our OUTPERFORM recommendaon and AUD$ 1.350 target price.
17 Nov 2021
Data highlights efti efficacy and potential central role in cancer therapy
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Data highlights efti efficacy and potential central role in cancer therapy
Data presented SITC (Society for Immunotherapy of Cancer) not only further supports eilagimod alpha ("ei") efficacy in metastac breast ("mBC") and head and neck ("HNSCC") cancers, but also highlights a potenal central role for ei across cancer therapy. Interim overall survival (“OS”) from the AIPAC was already posive, this final data is slightly improved with a clear 2.9 month increase in OS with ei+ paclitaxel. While this was not stascally significant, there was a significant increase in quality of life ("QoL") across the populaon and in OS in large paent subgroups amounng to 60% of the populaon. This included paents <65 years, those pre-treated with CDK 46 treatment, with luminal B or parcularly with a low starng monocyte count where there was an impressive 19.6-month OS increase. Further data from Phase IIa TACTI-002 supported the efficacy of ei-pembrolizumab ("ei-pembro") combinaon in HNSCC. These data not only supportthe connued development of ei in mBC in the AIPAC-03 Phase III andHNSCC in TACTI-003 Phase 2b, but also the broad potenal of ei combinaonsin cancertherapy. Safe and well tolerated ei is already showing synergy with an-PD-L1 and chemo, we believe analysis of the mBC subgroups could lead to addional combinaons; parcularly with agents that impact monocyte acvity. We reiterate and maintain our OUTPERFORM recommendaon and AUD$ 1.350 target price.